États-Unis · Bourse & Finance · The Motley Fool

Forget Zepbound: Eli Lilly's Next Weight-Loss Drug Could Be Its Biggest Blockbuster Yet

Publié par The Motley Fool · États-Unis il y a 12 h

Zepbound was a breakthrough. It became the first medicine to mimic the GLP-1 and GIP gut hormones and be approved for weight loss. Its main competitor, Wegovy, only mimics GLP-1.…

Lire l'article complet sur The Motley Fool Connectez-vous pour sauvegarder

MediaNews présente le titre et le résumé publiés par le média. L'article complet se lit sur le site de l'éditeur. (www.fool.com)

Forget Zepbound: Eli Lilly's Next Weight-Loss Drug Could Be Its Biggest Blockbuster Yet

À lire aussi

'Uptober' Starts Green as Bitcoin ETFs Draw $134 Million

Private Equity Firms Double Down on Fossil Fuels

American Airlines adds cash-and-miles bookings as loyalty battle heats up

Gen Z is poised to be wealthier than millennials but despair over economy — ‘they get spammed and scammed, and there are tons of fake jobs out there’

Toncoin (TON) Price Prediction 2025, 2026, 2027-2030

This NYC startup requires 4 days in office but just let everyone work remote for a whole month

Forget Zepbound: Eli Lilly's Next Weight-Loss Drug Could Be Its Biggest Blockbuster Yet

Partager

À lire aussi

'Uptober' Starts Green as Bitcoin ETFs Draw $134 Million

Private Equity Firms Double Down on Fossil Fuels

American Airlines adds cash-and-miles bookings as loyalty battle heats up

Gen Z is poised to be wealthier than millennials but despair over economy — ‘they get spammed and scammed, and there are tons of fake jobs out there’

Toncoin (TON) Price Prediction 2025, 2026, 2027-2030

This NYC startup requires 4 days in office but just let everyone work remote for a whole month